Black Diamond Therapeutics, Inc.
BDTX- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001701541
No open-market purchases or sales by Black Diamond Therapeutics, Inc. insiders were filed in the last 90 days; 96 institutions reported holding it in 13F filings for Q2 2026, worth $64.9M in total; no superinvestor holds it.
13F holders, Q3 2024
Institutional positions in Black Diamond Therapeutics, Inc. as of Sep 30, 2024. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 96
- +7 vs. Q2 2024
- Shares held
- 48.7M
- +5.17M (+11.9%) vs. Q2 2024
- Total value
- $211.9M
- +$8.97M (+4.4%) vs. Q2 2024
- New holders
- 23
- 37 more added
- Sold out
- 16
- 21 more reduced
1 institution that held it in Q2 2024 haven't filed for Q3 2024 yet. Not filing isn't selling, so they aren't counted as sold out or in the changes above.
Compare with Q2 2024: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting BDTX on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 96 | $64.9M |
| Q1 2026 | 104 | $82.0M |
| Q4 2025 | 104 | $92.0M |
| Q3 2025 | 91 | $147.0M |
| Q2 2025 | 94 | $95.8M |
| Q1 2025 | 85 | $63.0M |
| Q4 2024 | 88 | $102.5M |
| Q3 2024 | 96 | $211.9M |
| Q2 2024 | 90 | $217.9M |
| Q1 2024 | 88 | $199.9M |
| Q4 2023 | 76 | $107.1M |
| Q3 2023 | 73 | $106.8M |
| Q2 2023 | 74 | $209.2M |
| Q1 2023 | 50 | $40.6M |
| Q4 2022 | 59 | $37.9M |
| Q3 2022 | 69 | $36.3M |
| Q2 2022 | 74 | $52.9M |
| Q1 2022 | 87 | $63.5M |
| Q4 2021 | 95 | $123.7M |
| Q3 2021 | 101 | $206.3M |
| Q2 2021 | 102 | $309.6M |
| Q1 2021 | 113 | $705.5M |
Institutions, Q3 2024
Shares, value and share of portfolio for each institution holding Black Diamond Therapeutics, Inc.; share changes are against Q2 2024.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Verition Fund Management LLC | 0 | $0 | 0.00% | −125,250−100.0% | Sold out |
| Qube Research & Technologies Ltd | 0 | $0 | 0.00% | −123,034−100.0% | Sold out |
| Cantor Fitzgerald, L. P. | 0 | $0 | 0.00% | −105,039−100.0% | Sold out |
| Alpine Global Management, LLC | 0 | $0 | 0.00% | −35,583−100.0% | Sold out |
| Bank of Montreal | 0 | $0 | 0.00% | −28,593−100.0% | Sold out |
| Algert Global LLC | 0 | $0 | 0.00% | −28,501−100.0% | Sold out |
| Susquehanna International Group, LLP | 0 | $0 | 0.00% | −25,266−100.0% | Sold out |
| SG Americas Securities, LLC | 0 | $0 | 0.00% | −23,146−100.0% | Sold out |
| Marathon Trading Investment Management LLC | 0 | $0 | 0.00% | −19,116−100.0% | Sold out |
| Gsa Capital Partners LLP | 0 | $0 | 0.00% | −16,814−100.0% | Sold out |
| Man Group plc | 0 | $0 | 0.00% | −12,416−100.0% | Sold out |
| Newbridge Financial Services Group, Inc. | 0 | $0 | 0.00% | −500−100.0% | Sold out |
| BlackRock Inc. | – | – | – | – | Not filed |